Jiangsu Hansoh Pharmaceutical Group Co Ltd (Hansoh Pharma), a subsidiary of Hansoh Pharmaceutical Group Co Ltd, carries out the research, development, manufacturing and distribution of pharmaceutical drug products. It's products are available in the form of tablets, capsules, injections and anti-infective drugs for the therapeutic areas including diabetes, infectious diseases, central nervous system, oncology, gastrointestinal and cardiovascular indications. The company products include Donepezil Hydrochloride Tablets, Olanzapine Tablets, ambrisentan tablets, gemcitabine hydrochloride for injection, imatinib mesylate tablets, vinorelbine tartrate injection and repaglinide tablets, among others. Hansoh Pharma markets its products under Fulaidi, Fulairui, Fulaixin, Xintai, Zefei, Xinwei, Gainuo, Nuoxin, Zetan, Meifeng, Hengte and other brands. The company also operates research and development center in Shanghai, China. Hansoh Pharma is headquartered in Lianyungang, Jiangsu, China.
Headquarters
China
Address
9 Dongjin Road, Huaguoshan Avenue, Lianyungang, Jiangsu
Website
www.hspharm.com
Telephone
86 400 8285227
No of Employees
9,123
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
3692 (HKG)
Revenue (2022)
$1.4B
7.7%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
26.9%
(2022 vs 2021)
Market Cap*
$11.9B
Net Profit Margin (2022)
XYZ
17.8%
(2022 vs 2021)
* As of and is in US$
Jiangsu Hansoh Pharmaceutical Group Co Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Oncology: | Marketing Network | Fulaidi |
| Pulaile | Information Inquiry | Fulairui |
| Zefei | International Marketx | Xintai |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In March, the company expanded its partnership with Biotheus to utilize an anti-EGFR/cMet bispecific antibody in developing ADCs. |
| 2023 | Contracts/Agreements | In January, the company and Biocytogen Pharmaceuticals (Beijing) Co. Ltd entered into an agreement, in which Biocytogen will provide a license to Hansoh Pharma for its selected fully human antibody molecules against a designated target for development, manufacturing, and commercialization globally. |
| 2022 | Contracts/Agreements | In November, the company entered into a license and collaboration agreement with Biotheus for Biotheus' EGFR/MET bispecific antibody PM-1080 in Greater China. |
Competitor Comparison
| Key Parameters | Jiangsu Hansoh Pharmaceutical Group Co Ltd | Anhui Huangshan Capsule Co Ltd | Arcadia Biotechnology Co Ltd | Beijing Tide Pharmaceutical Co Ltd | Changchun GeneScience Pharmaceutical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | China |
| City | Lianyungang | Xuancheng | Shanghai | Beijing | Changchun |
| State/Province | Jiangsu | Anhui | Shanghai | Beijing | Jilin |
| No. of Employees | 9,123 | 645 | - | - | - |
| Entity Type | Public | Public | Private | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Zhong Huijuan | Chief Executive Officer; Director | Executive Board | 2015 | 61 |
| Lyu Aifeng | Director | Executive Board | 2016 | 45 |
| Sun Yuan | Director | Executive Board | 2015 | 35 |
| Hu Min | Chief Financial Officer | Senior Management | 2019 | 45 |
| Wu Qiong | Chief Medical Officer | Senior Management | - | 53 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward